COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
AN2728 Topical Ointment in Sensitive Areas of Healthy Volunteers
Scientific title
Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive Areas in Healthy Volunteers
Secondary ID [1] 273278 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriasis 279043 0
Condition category
Condition code
Skin 279230 279230 0 0
Dermatological conditions

Study type
Description of intervention(s) / exposure
AN2728 Topical Ointment, 2% will be applied to the specified areas (elbows, knees, groins, axillae, gluteal cleft, retroauricular areas, genitals and hairline) by the participants twice a day for 21 days.
Intervention code [1] 283623 0
Treatment: Drugs
Comparator / control treatment
Vehicle Ointment only without active ingredient.
Control group

Primary outcome [1] 279859 0
To assess the systemic safety and local tolerability of AN2728 Topical Ointment, 2% and vehicle ointment in sensitive areas of healthy volunteers.
Timepoint [1] 279859 0
At baseline and at Day 3, 7, 10, 14, 17 and 22 after starting AN2728 Topical Ointment, 2% or Vehicle Ointment. The outcomes will be assessed by treatment area focused examinations by a medical officer at each timepoint. Tolerability will be assessed by grading of local tolerability symptoms such as burning/stinging, pruritis and erythema according to a scale (0=None; 1=mild; 2=moderate; 3=severe; 0.5, 1.5 are 2.5 are midpoints between the defined grades).
Secondary outcome [1] 294594 0
Timepoint [1] 294594 0

Key inclusion criteria
1. Ability to understand and give written informed consent prior to the initiation of any protocol-related procedures.
2. Caucasian males and females, 18-55 years (inclusive) of age at the time of randomisation.
3. Willing and able to comply with study instructions and commit to all study visits.
Minimum age
18 Years
Maximum age
55 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. History of serious adverse reactions or hypersensitivity to any drug; or known allergy to any of the test product(s) or any components in the test product(s) or history of hypersensitivity; or allergic reactions to any of the study preparations as described in the IB.
2. Any clinically significant medical conditions or history of such conditions that, in the opinion of the Investigator may place the subject at an unacceptable risk as a participant in this trial.
3. Abnormal physical findings of clinical significance or dermatological condition at the Screening examination or Baseline which would interfere with the objectives of the study.
4. Clinically significant abnormal laboratory values (as determined by the Investigator) at the Screening evaluation.
5. Chronic use of medications that would interfere with the objectives of the study (such as antihistamines, corticosteroids, analgesics and anti-inflammatories)
within 1 week of Baseline and during the study.
6. Not willing to refrain from shaving, the use of depilatories or other hair-removal activities in the treatment areas 2 days prior to enrollment and during the course of the study.
7. Not willing to refrain from all sexual contact during the treatment period and 24 h after the last dose of study drug.
8. Uncircumcised males.
9. Females who are breastfeeding or pregnant, or who intend to become pregnant during the time of their participation in the study.
10. Concurrent or recent (within 60 days of randomization) participation in another drug or device research study.
11. Considered by the Investigator to be unsuitable candidate for this study.
12. Use of AN2728 in a previous clinical trial.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 284109 0
Commercial sector/Industry
Name [1] 284109 0
Anacor Pharmaceuticals, Inc
Address [1] 284109 0
1020 East Meadow Circle
Palo Alto California 94303
Country [1] 284109 0
United States of America
Primary sponsor type
Commercial sector/Industry
CMAX - A division of IDT Australia, Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Secondary sponsor category [1] 269071 0
Name [1] 269071 0
Address [1] 269071 0
Country [1] 269071 0

Ethics approval
Ethics application status
Ethics committee name [1] 272061 0
Bellberry Limited
Ethics committee address [1] 272061 0
229 Greenhill Road
Dulwich SA 5065
Ethics committee country [1] 272061 0
Date submitted for ethics approval [1] 272061 0
Approval date [1] 272061 0
Ethics approval number [1] 272061 0

Brief summary
The aim of this study is to assess the local tolerability of an experimental ointment called AN2728. This ointment has been tested in 11 clinical trials to date, and is being developed as a treatment for patients with psoriasis. In the laboratory this ointment has been shown to reduce inflammatory chemicals in the body that are involved in inflammatory skin diseases.
This study will help doctors find out how well people will tolerate the application of the ointment to sensitive areas in terms of any local reaction (ie. irritation, redness, itchiness). Participant's skin will be monitored closely at various times throughout the study to assess any effect that the drug has on their skin.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 33317 0
Address 33317 0
Country 33317 0
Phone 33317 0
Fax 33317 0
Email 33317 0
Contact person for public queries
Name 16564 0
Louise Pirc
Address 16564 0
CMAX - A division of IDT Australia, Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Country 16564 0
Phone 16564 0
Fax 16564 0
Email 16564 0
Contact person for scientific queries
Name 7492 0
Sepehr Shakib
Address 7492 0
CMAX - A division of IDT Australia, Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000
Country 7492 0
Phone 7492 0
Fax 7492 0
Email 7492 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary